Moreover, results from multiple clinical trials have confirmed the significant therapeutic effects of anti-CTLA-4 and anti-PD-1/PD-L1 inhibitors on NSCLC [8–12]. Here, PDCD1 is linked to non-small cell lung carcinoma.